Wanbury Ltd

Wanbury announced that a routine current Good Manufacturing Practices ( cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the company's facility at Tanuku, West Godavari District, Andhra Pradesh during the period from 13 July 2026 to 17 July 2026. At the conclusion of the inspection, the U.S.FDA has issued a Form 483 with six observations. The Company will respond to these observations to FDA within the stipulated time.

Wanbury Ltd lost 6.43% today to trade at Rs 318. The BSE Healthcare index is down 0.22% to quote at 50230.53. The index is up 4.99 % over last one month. Among the other constituents of the index, Bliss GVS Pharma Ltd decreased 4.47% and Bajaj Healthcare Ltd lost 1.82% on the day. The BSE Healthcare index went up 11.67 % over last one year compared to the 5.54% fall in benchmark SENSEX. Wanbury Ltd has added 19.28% over last one month compared to 4.99% gain in BSE Healthcare index and 1.1% rise in the SENSEX. On the BSE, 7073 shares were traded in the counter so far compared with average daily volumes of 39225 shares in the past one month. The stock hit a record high of Rs 360 on 15 Jul 2026. The stock hit a 52-week low of Rs 162 on 27 Jan 2026.

Wanbury Ltd gained 3.27% today to trade at Rs 347.1. The BSE Healthcare index is up 0.5% to quote at 50452.09. The index is up 6.97 % over last one month. Among the other constituents of the index, Anuh Pharma Ltd increased 2.62% and Fabtech Technologies Ltd added 2.43% on the day. The BSE Healthcare index went up 11.25 % over last one year compared to the 6.51% fall in benchmark SENSEX. Wanbury Ltd has added 29.93% over last one month compared to 6.97% gain in BSE Healthcare index and 1.22% rise in the SENSEX. On the BSE, 36855 shares were traded in the counter so far compared with average daily volumes of 27275 shares in the past one month. The stock hit a record high of Rs 352.95 on 15 Jul 2026. The stock hit a 52-week low of Rs 162 on 27 Jan 2026.Powered by Capital Market - Live

Wanbury announced the company has expanded regulatory submission for launch of new Active Pharmaceuticals Ingredients (APIs). For Diphenhydramine HCl, company submitted DMF to Malaysia and Singapore. The Company proposed to explore new market opportunities for Paroxetine HCl in Korea and Latin America by submitting the DMFs. Company also received formal audit report from MFDS (Korea FDA) for its Patalganga facility stating zero observation for the inspection conducted in April 2026.

Net profit of Wanbury rose 7.11% to Rs 21.70 crore in the quarter ended March 2026 as against Rs 20.26 crore during the previous quarter ended March 2025. Sales declined 4.31% to Rs 164.58 crore in the quarter ended March 2026 as against Rs 172.00 crore during the previous quarter ended March 2025. For the full year,net profit rose 116.61% to Rs 66.13 crore in the year ended March 2026 as against Rs 30.53 crore during the previous year ended March 2025. Sales rose 8.47% to Rs 650.27 crore in the year ended March 2026 as against Rs 599.51 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales164.58172.00 -4 650.27599.51 8 OPM %18.1317.23 -16.4212.73 - PBDT21.9922.43 -2 77.7142.86 81 PBT18.7619.06 -2 63.4029.55 115 NP21.7020.26 7 66.1330.53 117 Powered by Capital Market - Live

Wanbury will hold a meeting of the Board of Directors of the Company on 14 May 2026.

The launch comes in response to recent Drug Controller General of India restrictions on fixed-dose cold combinations for children under four years. The move strengthens Wanbury's Coriminic brand and positions the company to capture a larger share of the pediatric cold care market. The new drops provide targeted relief from allergic symptoms such as severe cold, blocked nose, and sneezing, while aligning with regulatory safety guidelines. The company is also expanding the Coriminic range with Coriminic NS (Normal Saline) Nasal Drops, a non-systemic nasal decongestant designed to provide localised relief from nasal congestion in children. These launches aim to help physicians navigate treatment options within regulatory guidelines while ensuring pediatric safety. The move positions Wanbury to capture a significant portion of India's Rs 861 crore Cold Preparation Liquid market, particularly in the pediatric segment. Coriminic CPM Drops provide targeted relief from allergic symptoms such as severe cold, blocked nose, and sneezing, aligning with rational prescribing practices and government safety advisories. Wanbury's initiative marks the first India-focused effort to reposition Chlorpheniramine in a safer, indication-driven format for children, consolidating the company's presence in the fast-growing pediatric cold care segment. The company continues to focus on delivering high-quality, affordable healthcare solutions across key therapeutic areas, including pediatrics. Wanbury is engaged in the business of pharmaceutical and related activities, including research. The company's consolidated net profit zoomed 1197.1% to Rs 13.49 crore on 24.5% rise in revenue from operations to Rs 163.18 crore in Q3 FY26 over Q3 FY25. Powered by Capital Market - Live

Net profit of Wanbury rose 1191.80% to Rs 15.76 crore in the quarter ended December 2025 as against Rs 1.22 crore during the previous quarter ended December 2024. Sales rose 21.73% to Rs 162.45 crore in the quarter ended December 2025 as against Rs 133.45 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales162.45133.45 22 OPM %16.4310.45 - PBDT19.614.61 325 PBT15.871.29 1130 NP15.761.22 1192 Powered by Capital Market - Live

Wanbury will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live

Wanbury announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 5 January 2026.Powered by Capital Market - Live